These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 2668355)

  • 21. [Activation of epidermal melanocytes is independent of epithelial proliferation and vascularization. Immunohistologic study using HMB-45 antibody with review of the literature].
    Lommel K; Tronnier M; Wolff HH
    Hautarzt; 1996 Aug; 47(8):616-23. PubMed ID: 8964704
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Re-excisions of scar in primary cutaneous melanoma: a histopathological study.
    Fallowfield ME; Cook MG
    Br J Dermatol; 1992 Jan; 126(1):47-51. PubMed ID: 1536761
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HMB-45 staining of dysplastic melanocytic nevi in melanoma risk groups.
    Ahmed I; Piepkorn M; Goldgar DE; Cannon-Albright LA; Meyer LJ; Skolnick MH; Zone JJ
    J Cutan Pathol; 1991 Aug; 18(4):257-60. PubMed ID: 1939784
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Melanocytic activation in HIV-1 disease: HMB-45 staining in common acquired nevi. Military Medical Consortium for the Advancement of Retroviral Research.
    Smith KJ; Skelton HG; Heimer W; Baxter D; Angritt P; Frisman D; Wagner KF
    J Am Acad Dermatol; 1993 Oct; 29(4):539-44. PubMed ID: 7691905
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Melanocytic hyperplasia associated with surgical scars in basal cell carcinoma re-excision specimens: A single-center retrospective study.
    Farah M; Suzuki S; Bhawan J
    J Cutan Pathol; 2022 Jan; 49(1):7-16. PubMed ID: 34269471
    [TBL] [Abstract][Full Text] [Related]  

  • 26. SM5-1: a new monoclonal antibody which is highly sensitive and specific for melanocytic lesions.
    Trefzer U; Rietz N; Chen Y; Audring H; Herberth G; Siegel P; Reinke S; Königer P; Wu S; Ma J; Liu Y; Wang H; Sterry W; Guo Y
    Arch Dermatol Res; 2000 Dec; 292(12):583-9. PubMed ID: 11214818
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Micro-anatomy related antigen expression in melanocytic lesions.
    Meije CB; Mooi WJ; Le Poole IC; Van Muijen GN; Das PK
    J Pathol; 2000 Apr; 190(5):572-8. PubMed ID: 10727983
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Melanocytes express 3G5 surface antigen.
    Fiedler E; Nayak RC; Marsch WCh; Helmbold P
    Am J Dermatopathol; 2004 Jun; 26(3):200-4. PubMed ID: 15166506
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Melan-A: not a helpful marker in distinction between melanoma in situ on sun-damaged skin and pigmented actinic keratosis.
    El Shabrawi-Caelen L; Kerl H; Cerroni L
    Am J Dermatopathol; 2004 Oct; 26(5):364-6. PubMed ID: 15365366
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The differential reactivity of benign and malignant nevomelanocytic lesions with mouse monoclonal antibody TNKH1.
    Nakanishi T; Hashimoto K
    Cancer; 1987 Apr; 59(7):1340-4. PubMed ID: 3545436
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Protein Expression Analysis of Melanocyte Differentiation Antigen TRP-2.
    Avogadri F; Gnjatic S; Tassello J; Frosina D; Hanson N; Laudenbach M; Ritter E; Merghoub T; Busam KJ; Jungbluth AA
    Am J Dermatopathol; 2016 Mar; 38(3):201-7. PubMed ID: 26894771
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Distribution of laminin and collagen type-IV in benign and malignant lesions of melanocytic origin.
    Natali PG; Nicotra MR; Bellocci M; Cavaliere R; Bigotti A
    Int J Cancer; 1985 Apr; 35(4):461-7. PubMed ID: 3886560
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression of the tumor suppressor gene product p16INK4 in benign and malignant melanocytic lesions.
    Keller-Melchior R; Schmidt R; Piepkorn M
    J Invest Dermatol; 1998 Jun; 110(6):932-8. PubMed ID: 9620301
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Microphthalmia transcription factor: a sensitive and specific marker for malignant melanoma in cytologic specimens.
    Dorvault CC; Weilbaecher KN; Yee H; Fisher DE; Chiriboga LA; Xu Y; Chhieng DC
    Cancer; 2001 Oct; 93(5):337-43. PubMed ID: 11668469
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Analysis of HLA antigen expression in benign and malignant melanocytic lesions reveals that upregulation of HLA-G expression correlates with malignant transformation, high inflammatory infiltration and HLA-A1 genotype.
    Ibrahim EC; Aractingi S; Allory Y; Borrini F; Dupuy A; Duvillard P; Carosella ED; Avril MF; Paul P
    Int J Cancer; 2004 Jan; 108(2):243-50. PubMed ID: 14639610
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Determination of proliferating fractions in malignant melanomas by anti-PCNA/cyclin monoclonal antibody.
    Takahashi H; Strutton GM; Parsons PG
    Histopathology; 1991 Mar; 18(3):221-7. PubMed ID: 1675189
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The recognition of UV-irradiation melanocyte with HMB-45 monoclonal antibody.
    Cheng H; Sun GJ; Thiele B; Wolff HH
    Chin Med J (Engl); 1994 Mar; 107(3):225-9. PubMed ID: 8088186
    [TBL] [Abstract][Full Text] [Related]  

  • 38. S100-positive spindle cells in scars: a diagnostic pitfall in the re-excision of desmoplastic melanoma.
    Chorny JA; Barr RJ
    Am J Dermatopathol; 2002 Aug; 24(4):309-12. PubMed ID: 12142609
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Melan-A positive dermal cells in malignant melanoma in situ.
    Danga ME; Yaar R; Bhawan J
    J Cutan Pathol; 2015 Jun; 42(6):388-93. PubMed ID: 25726939
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression and ultrastructural localization of HMB-45 antigen.
    Kikuchi A; Shimizu H; Nishikawa T
    Br J Dermatol; 1996 Sep; 135(3):400-5. PubMed ID: 8949433
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.